-
1
Investigations sur une crise de mortalité à Boulogne-sur-Mer (Pas-de-Calais, XVIIIe s.). Hypothèses d’interprétation
Published 2007-06-01“…Seven simultaneous burials, representing a total of 39 individuals and dated as early as the 18th century, were found at the excavation site of l’Ilot Saint-Louis at Boulogne-sur-Mer (Pas-de-Calais). The simultaneity of the bone deposits, the contemporaneity of the different burial structures and the recurrence of the phenomenon lead us to believe that the site is the result of an abrupt peak in mortality. …”
Get full text
Article -
2
-
3
-
4
Elicitation of Roots and AC-DC with PEP-13 Peptide Shows Differential Defense Responses in Multi-Omics
Published 2022-08-01Get full text
Article -
5
Biological and Chemical Characterization of <i>Musa paradisiaca</i> Leachate
Published 2023-10-01Get full text
Article -
6
LAM2: An Unusual Laminaran Structure for a Novel Plant Elicitor Candidate
Published 2023-10-01Get full text
Article -
7
-
8
-
9
Awe and the Experience of the Sublime: A Complex Relationship
Published 2020-06-01Get full text
Article -
10
-
11
Psychometric Properties of the Competencies Compound Inventory for the Twenty-First Century
Published 2022-06-01Get full text
Article -
12
DevOps Model Appproach for Monitoring Smart Energy Systems
Published 2022-07-01Get full text
Article -
13
Trends in International Cancer Research Investment 2006-2018
Published 2021-12-01Get full text
Article -
14
-
15
-
16
Educational Robotics and Robot Creativity: An Interdisciplinary Dialogue
Published 2021-06-01Get full text
Article -
17
-
18
Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
Published 2023-08-01Get full text
Article -
19
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
Published 2016-06-01“…The preclinical efficacy results led to a fast-track clinical development. The US Food and Drug Administration (FDA) approval was achieved after the Phase I clinical trial in 2011 in ALK-rearranged advanced NSCLC progressing after a first-line treatment. …”
Get full text
Article -
20